| Bioactivity | Bulevirtide (Myrcludex B) is a NTCP inhibitor, a linear lipopeptide of 47 amino acids. Bulevirtide inhibits HBV and HDV entry into liver cells, blocks HBV infection in hepatocytes, and participates in HBV transcriptional suppression. Bulevirtide can be used in HDV infection and compensated cirrhosis research[1][2]. | ||||||
| Name | Bulevirtide | ||||||
| CAS | 2012558-47-1 | ||||||
| Shortening | {Myr}-GTNLSVPNPLGFFPDHQLDPAFGANSNNPDWDFNPNKDHWPEANKVG-NH2 | ||||||
| Formula | C234H329N65O71 | ||||||
| Molar Mass | 5398.86 | ||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||
| Storage | Sealed storage, away from moisture and light, under nitrogen
*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen) |
Bulevirtide
CAS: 2012558-47-1 F: C234H329N65O71 W: 5398.86
Bulevirtide (Myrcludex B) is a NTCP inhibitor, a linear lipopeptide of 47 amino acids. Bulevirtide inhibits HBV and HDV
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.